---
document_datetime: 2025-11-07 10:11:59
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zoledronic-acid-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zoledronic-acid-mylan-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.7424468
conversion_datetime: 2025-12-14 14:18:11.76712
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Zoledronic acid Mylan

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | Notification acc.Article61(3)-Accepted | 06/11/2025                          |                                          | PL                              |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3SmPC(Summary ofProductCharacteristics),AnnexII,Labelling,PL(PackageLeaflet).

2 A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics, annexII, labelling,package leaflet).The CDisissuedwithintwomonths of the opinionforvariationsfallingunderthescope ofArticle23.1a(a)ofRegulation(EU)No.712/2012,orwithinoneyearforotherprocedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/N/0000310108                      | Update of the package leaflet with revised contactdetailsoflocalrepresentative and deletion of 'United Kingdom (Northern Ireland)' from the list of local representatives in line with the QRD template v10.4.   |            |     |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| Variation type II / EMA/VR/0000248431 | B.I ACTIVE SUBSTANCE-B.I.zSubstantial updates to Mod. 3.2.S or the ASMF - Accepted                                                                                                                               | 05/06/2025 | N/A |